Recent preclinical data have demonstrated that pancreatic adenocarcinoma (PDA) cells with
defects in the Fanconi anemia/BRCA2 pathway are hypersensitive to interstrand …

Abstract Background: Pancreatic cancer (PDAC)–even if deemed resectable–has still a
dismal prognosis and is the seventh leading cause of global cancer-related death with rising …

Abstract Purpose: BRCA2, FANCC, and FANCG gene mutations are present in a subset of
pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross …

Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …

Outcomes in pancreatic ductal adenocarcinoma (PDAC) remain poor due to a variety of
biological, clinical, and societal factors. However, in recent years, PDAC has seen 1) …

Pancreatic ductal adenocarcinoma remains an unyielding adversary, with a 5-year survival
of 5%, a figure unchanged in 50 years. Characterised by marked genetic heterogeneity …

Context Pancreatic cancer (PDAC) is one of the most challenging cancers to treat with
modest recent improvements in survival from new systemic therapies. There is growing …

Modern anti-cancer therapies using specific kinase inhibitors are directed towards critical
molecular targets that are involved in tumor progression and resistance towards cytotoxic …

Pancreatic ductal adenocarcinoma (PDAC) is a highly heterogeneous tumor comprising
pancreatic cancer cells, fibroblasts, immune cells, vascular epithelial cells, and other cells in …

The incidence of pancreatic ductal adenocarcinoma (PDAC) is steadily increasing and the
annual death‐to‐incidence ratio approaches one. This is a figure that has not changed for …